Given their central role in cell health, mitochondria have become increasingly relevant targets for therapies aimed at addressing various disorders, including neurodegenerative diseases, metabolic disorders, and neuroinflammatory processes. Consequently, for pharma and biotech establishing a pharmacological approach to mitochondrial function, there is a pressing need for high-quality assays capable of interrogating mitochondrial function comprehensively.

Download this collection of real world data by Sygnature Discovery's mitochondrial expert, Dr. Tatiana Rosenstock. Understand how to measure mitochondria and why it's important to do so.

Bio_TR 2

About Tatiana 

Tatiana Rosenstock has had an exceptional career and has made significant contributions to the field of Neuroscience for 20+ years. Her work has focused on topics such as mitochondrial deregulation, transcription deregulation, and autophagy in neurodegenerative diseases, such as Huntington’s Disease, and Amyotrophic Lateral Sclerosis, and Schizophrenia.  

At Sygnature Discovery, Tatiana is a Principal Scientist overseeing various neuroscience-related projects in different sub-areas such as metabolism (mitochondrial function), biomarkers, microglial function and activation, and neuroplasticity. During this period, she has been working with distinct in-vitro models, named iPSC-derived neurons, primary cortical neurons, Alzheimer`s and Parkinson`s disease fibroblasts, neuroblastomas cell lines, tissue and biofluids from transgenics animal models of Alzheimer`s disease. 

Watch Tatiana's #MitochondriaUnlocked LinkedIn video series 

Follow our 5-part LinkedIn series throughout April and May to explore mitochondrial function and download the real world data report above to receive comprehensive insights from Tatiana

Mitochondrial Related Assays at Sygnature Discovery

Sygnature Discovery employs an agnostic approach to mitochondrial assays, recognizing the universal importance of mitochondria across different cell types and diseases. This strategy facilitates a broad understanding of mitochondrial biology, aiding in the development of targeted interventions.

We offer a state-of-the-art in vitro assay platform to advance drug discovery efforts targeting mitochondrial function. Our platform provides a comprehensive suite of assays and endpoints tailored to elucidate key aspects of mitochondrial function and health. By leveraging these innovative assays, researchers can gain deeper insights into mitochondrial biology and develop novel therapeutics targeting mitochondrial dysfunction. Experience personalised support and the difference of working with a trusted partner dedicated to accelerating your therapeutic development journey.

  • Cytosolic Calcium Evaluation 
  • Mitochondrial Membrane Potential Measurement 
  • Oxidative Stress Levels Measurement 
  • Mitochondrial Dynamics and Biogenesis Evaluation 
  • Energetic Compound Measurements
  • Lysosomal Deregulation and Mitochondrial Quality Control
  • Oxygen Consumption Rate and Extracellular Acidification Rate

A History of Innovation

Since its founding in 2004, the integrated drug discovery team at Sygnature Discovery has delivered over 40 preclinical compounds and 25 clinical compounds. Our scientists are named on over 170 customer patent applications.

Performance Graphs Feb24-02